Prostate Adenocarcinoma Articles & Analysis
2 news found
BXCL701 is being evaluated in combination with KEYTRUDA® (pembrolizumab) in an ongoing Phase 2 trial in metastatic castration-resistant prostate cancer (mCRPC) patients with either adenocarcinoma or small cell neuroendocrine carcinoma (SCNC) phenotype. ...
(Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced results from its ongoing Phase 2 trial of BXCL701, the Company's investigational, oral innate immunity activator, in metastatic castration-resistant prostate cancer (mCRPC) patients with ...